Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
Rett-icent Neurological Disorder Reveals Some Secrets

8 February 2006. Rett syndrome is a rare neurodevelopmental disorder that has been linked to autism (see Shibayama et al., 2004) and at least one incidence of childhood-onset schizophrenia (see Cohen et al., 2002). In most cases the syndrome can be traced to loss-of-function mutations in the gene coding for methyl-CpG binding protein 2 (Mecp2), a multitasker that both represses transcription and regulates mRNA splicing (see SRF related news story). However, beyond this detailed job description, it is still unclear why Mecp2 mutations cause this devastating disease. In the February 2 Neuron, Rudolph Jaenisch and colleagues at the Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, offer an explanation that at first blush appears to be counterintuitive. They report that Rett-like symptoms in mice harboring mutations in the repressor correlate with reduced levels of brain-derived neurotrophic factor (BDNF), rather than increased levels of the neurotrophin as one might expect. The findings indicate that the wild-type repressor somehow boosts BDNF in the normal brain and suggest that elevating the neurotrophin may be a therapeutic strategy to help patients suffering from the disease. In fact, by overexpressing BDNF, Jaenisch and colleagues were able to slow the onset and reduce the severity of disease in Mecp2 mutant mice. Curiously, both reductions in BDNF (see Durany et al., 2001) and BDNF-positive neurons (see Iritani et al., 2003) have also been linked to schizophrenia.

Two years ago, Jaenisch and colleagues reported that wild-type Mecp2 shuts off BDNF transcription (see Chen et al., 2003). This is what makes the current finding so interesting, because one would expect that to restore normal neurodevelopment in Mecp2 mutant mice—which lack the methyl CpG binding domain—one would have to decrease BDNF levels. But hints that the Mecp2/BDNF relationship may not be so simple came when the Jaenisch team began characterizing Mecp2 mutant animals. First author Qiang Chang and colleagues found that total brain BDNF dropped in these animals just when they started showing the first symptoms of disease, at around 6-8 weeks old.

To investigate this further, the researchers asked what would happen if they reduced BDNF in normal animals. Because BDNF knockouts are lethal, Chang and colleagues addressed this question by using BDNF conditional knockouts developed a few years ago in the Jaenisch lab. These animals retain the neurotrophin during embryonic development, but then lose it shortly after birth. Chang found that BDNF conditional knockout (cKO) mice recapitulated some of the symptoms of Mecp2 mutant mice, including low brain weight, reduced size of hippocampal CA2 neurons, and repetitive hind limb clasping, which is thought to mimic the hand-wringing behavior typically found in children with Rett’s. In addition, when Chang and colleagues crossed these cKO mice with Mecp2-negative animals, they found that the double knockout animals had a much shorter lifespan than wild-type or mice lacking only Mecp2. The double knockouts also had much earlier onset of locomotor symptoms.

If loss of BDNF mimics the effects of Mecp2 mutations, then might topping up levels of the neurotrophin not relieve some of the symptoms? This is exactly what Chang and colleagues found. When they made a conditional mutant mouse that overexpressed BDNF shortly after birth, then crossed this with Mecp2 mutant animals, the offspring, which produced around twice as much of the neurotrophin as normal, developed Rett-like symptoms later in life. They lived longer than the Mecp2 mutants, and the BDNF boost also increased their locomotor activity and brain weight.

The big question is why lack of the transcriptional repressor should lead to loss of BDNF in the brain in the first place, given that it has exactly the opposite effect in cultured neurons. The explanation for this seems to be related to experimental conditions. Chang and colleagues point out that in their initial experiments, the effect of Mecp2 on BDNF expression was measured in neurons that were artificially silenced. In the brain, however, neuronal activity is known to have a huge impact on BDNF expression. “Given that BDNF expression depends on neuronal activity, we favor the hypothesis that Mecp2 deficiency reduces neuronal activity, thereby indirectly causing a decreased BDNF protein level,” write the authors. In support of this, they found that the firing rate of neurons in layer five of the cortex is reduced in Mecp2 animals by about fourfold, and that overexpression of BDNF partly restored it. The next step will be to find out why Mecp2 mutations reduce neuronal activity.

Whether these latest findings have any specific relevance to schizophrenia is unclear. However, given that both BDNF and Mecp2 have been linked to various psychological and neurological disorders, the relationship between the two genes may well be worth following.—Tom Fagan.

Reference:
Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron February 2, 2006;49:341-348. Abstract

 
Comments on News and Primary Papers
Comment by:  Mary Reid
Submitted 9 February 2006 Posted 10 February 2006

The suggestion by Rudolph Jaenisch and colleagues that...  Read more


View all comments by Mary Reid

Comment by:  Mary Reid
Submitted 13 March 2007 Posted 14 March 2007

I had proposed that mutations in MECP2 may result in...  Read more


View all comments by Mary Reid
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright